Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Insulin Degludec (Tresiba) vs Insulin Lispro (Humalog)
An educational, source-based comparison of Insulin Degludec (Tresiba) and Insulin Lispro (Humalog) — how each peptide works, what it's researched for, and what to know before going deeper.
Ultra-long-acting basal insulin with >42-hour duration.
Insulin analog with a hexadecanedioic acid side chain at LysB29 that forms soluble multi-hexamers at the injection site, releasing monomers slowly for flat, prolonged action.
- Basal insulin therapy
- Flexible dosing schedules
- Reduced nocturnal hypoglycemia
- • FDA-approved.
- • Steady state reached after ~3 days.
Recombinant insulin analog with reversed lysine and proline at B28/B29, reducing self-association so it acts within ~15 minutes for postprandial glucose control.
- Prandial coverage in T1D/T2D
- Insulin pump therapy
- Hyperglycemic crises (with caution)
- • FDA-approved.
- • Hypoglycemia risk if meal delayed or skipped.
Insulin Degludec (Tresiba) vs Insulin Lispro (Humalog) — Key differences
- Class: Insulin Degludec (Tresiba) is classified as Insulin Analog · Endocrine, while Insulin Lispro (Humalog) is Insulin Analog · Endocrine.
- Primary research focus: Insulin Degludec (Tresiba) — basal insulin therapy; Insulin Lispro (Humalog) — prandial coverage in t1d/t2d.
- Tag: FDA-Approved · Diabetes vs FDA-Approved · Diabetes.